A
Achille Aouba
Researcher at University of Caen Lower Normandy
Publications - 208
Citations - 4722
Achille Aouba is an academic researcher from University of Caen Lower Normandy. The author has contributed to research in topics: Vasculitis & Medicine. The author has an hindex of 29, co-authored 179 publications receiving 3593 citations. Previous affiliations of Achille Aouba include Necker-Enfants Malades Hospital & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort
Cloé Comarmond,Christian Pagnoux,Mehdi Khellaf,Jean-François Cordier,Mohamed Hamidou,Jean-François Viallard,François Maurier,Stéphane Jouneau,Boris Bienvenu,Xavier Puéchal,Olivier Aumaître,Guillaume Le Guenno,Alain Le Quellec,Ramiro Cevallos,Olivier Fain,Bertrand Godeau,Raphaèle Seror,Bertrand Dunogué,Alfred Mahr,Philippe Guilpain,Pascal Cohen,Achille Aouba,Luc Mouthon,Loïc Guillevin +23 more
TL;DR: Although EGPA relapses remain frequent, mortality has declined, at least since 1996, and multivariable analysis identified cardiomyopathy, older age, and diagnosis during or prior to 1996 as independent risk factors for death and lower eosinophil count at diagnosis as predictive of relapse.
Journal ArticleDOI
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome
Raphaèle Seror,Christelle Sordet,Loïc Guillevin,Eric Hachulla,Charles Masson,Marc Ittah,Sophie Candon,Véronique Le Guern,Achille Aouba,Jean Sibilia,Jacques-Eric Gottenberg,Xavier Mariette +11 more
TL;DR: Good efficacy and fair tolerance of rituximab for systemic symptoms in patients with primary Sjögren’s syndrome are shown, and RTX allows for a marked reduction in corticosteroid use.
Journal ArticleDOI
Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
Achille Aouba,A. Baldolli,Loïk Geffray,Renaud Verdon,Emmanuel Bergot,Nicolas Martin-Silva,Aurélien Justet +6 more
TL;DR: It is proposed that targeting IL-1 should be a safe and effective approach to avoid mechanic ventilation in patients with moderate to severe COVID-19 pneumonia hospitalised in a non-intensive care unit (ICU) and proposed anti-IL-1 blocking by anakinra to nine patients.
Journal ArticleDOI
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
D. Saadoun,Felipe Suarez,François Lefrère,Françoise Valensi,Xavier Mariette,Achille Aouba,Caroline Besson,Bruno Varet,Xavier Troussard,Patrice Cacoub,Olivier Hermine +10 more
TL;DR: The role of HCV in the lymphomagenesis and the benefit of antiviral treatment for patients presenting with HCV-driven lymphoproliferations are underscored.
Journal ArticleDOI
Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease.
Achille Aouba,Achille Aouba,Sophie Georgin-Lavialle,Christian Pagnoux,Nicolas Martin Silva,Amédée Renand,Françoise Galateau-Salle,Sophie Le toquin,Henri Bensadoun,Frédérique Larousserie,Stéphane Silvera,Nicole Provost,Sophie Candon,Raphaèle Seror,Mathilde de Menthon,Olivier Hermine,Loïc Guillevin,Boris Bienvenu +17 more
TL;DR: A central role of the IL-1 network, which seemed to be overstimulated in ECD, is supported and its specific blockade using anakinra thereby opens new pathophysiology and therapeutic perspectives in E CD.